Treats obsessions and compulsions. ANDA 211767, held by Mankind Pharma. Clomipramine Hydrochloride.
As of Nov 16, 2026, ANDA 211767 (Clomipramine Hydrochloride), held by Mankind Pharma, was first approved by FDA on Apr 8, 2019, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 8, 2019 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Oct 13, 2023 | Supplement 15Manufacturing | Approved | None posted |
| Sep 21, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 21, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 21, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters